

Table 1.22
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2012^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			37-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 37 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 37 Years ^d
All Sites	Both Sexes	4,660,390	4,751,475	5,238,866	13,405,317	13,624,510
	Male	2,395,057	2,430,935	2,669,928	6,387,558	6,462,521
	Female	2,265,333	2,320,540	2,568,938	7,017,759	7,161,989
Oral Cavity & Pharynx	Both Sexes	108,762	126,337	131,109	282,380	312,792
	Male	76,856	88,637	91,609	188,848	207,488
	Female	31,906	37,700	39,500	93,532	105,304
Esophagus	Both Sexes	21,344	26,589	26,680	35,667	42,388
	Male	16,607	20,581	20,639	27,750	32,814
	Female	4,737	6,008	6,041	7,917	9,574
Stomach	Both Sexes	37,369	45,065	45,492	75,640	87,222
	Male	22,014	27,032	27,269	43,300	50,402
	Female	15,355	18,033	18,223	32,340	36,820
Colon & Rectum	Both Sexes	398,737	458,984	468,251	1,149,814	1,279,479
	Male	204,170	234,705	239,034	573,302	635,108
	Female	194,567	224,279	229,217	576,512	644,371
Liver & Intrahepatic Bile Duct	Both Sexes	36,620	41,939	41,976	50,271	56,613
	Male	27,039	30,599	30,620	35,990	40,166
	Female	9,581	11,340	11,356	14,281	16,447
Pancreas	Both Sexes	34,042	41,747	41,771	45,432	54,507
	Male	17,628	21,807	21,819	22,666	27,478
	Female	16,414	19,940	19,952	22,766	27,029
Larynx	Both Sexes	31,457	37,206	37,786	87,479	98,015
	Male	25,542	30,220	30,728	70,303	78,592
	Female	5,915	6,986	7,058	17,176	19,423
Lung & Bronchus	Both Sexes	233,827	301,827	311,522	402,326	498,404
	Male	107,351	140,977	144,670	180,530	225,061
	Female	126,476	160,850	166,852	221,796	273,343
Melanoma of the Skin	Both Sexes	285,569	326,073	342,024	962,438	1,041,311
	Male	153,364	179,735	189,728	478,737	525,778
	Female	132,205	146,338	152,296	483,701	515,533
Breast	Female	872,541	944,632	1,005,580	2,928,546	3,104,561
Cervix	Female	39,323	41,561	41,655	214,008	220,136
Corpus & Uterus, NOS	Female	183,434	205,521	205,655	598,766	653,998
Ovary ^f	Female	59,878	68,736	68,817	177,706	199,493

^a U.S. 2012 cancer prevalence counts are based on 2012 cancer prevalence proportions from the SEER 9 registries and 1/1/2012 U.S. population estimates based on the average of 2011 and 2012 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 37 years (1975-2011)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2007-2011)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2007; Melanoma in 2008.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 37-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2012.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 37-year limited duration prevalence. The 2007 breast cancer is counted for the breast 5-year and 37-year limited duration prevalence.

In method (e) the 2007 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2008 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.22 - continued
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2012^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			37-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 37 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 37 Years ^d
Prostate	Male	1,044,262	1,128,141	1,128,224	2,794,570	2,976,626
Testis	Male	42,435	43,354	44,013	218,903	221,980
Urinary Bladder	Both Sexes	201,191	253,322	258,716	567,531	664,041
	Male	153,198	193,786	198,124	424,112	496,868
	Female	47,993	59,536	60,592	143,419	167,173
Kidney & Renal Pelvis	Both Sexes	154,353	188,076	190,370	365,660	427,078
	Male	94,867	117,507	119,055	217,927	257,221
	Female	59,486	70,569	71,315	147,733	169,857
Brain & Nervous System	Both Sexes	45,479	48,676	49,045	136,100	140,756
	Male	24,643	26,423	26,633	72,270	74,764
	Female	20,836	22,253	22,412	63,830	65,992
Thyroid	Both Sexes	185,714	207,444	208,227	563,884	604,543
	Male	40,645	47,892	48,044	121,802	134,236
	Female	145,069	159,552	160,183	442,082	470,307
Hodgkin Lymphoma	Both Sexes	38,167	40,722	40,777	176,990	181,967
	Male	20,781	22,226	22,270	91,797	94,359
	Female	17,386	18,496	18,507	85,193	87,608
Non-Hodgkin Lymphoma	Both Sexes	205,597	242,575	245,938	541,393	606,972
	Male	110,512	131,592	133,324	284,672	319,941
	Female	95,085	110,983	112,614	256,721	287,031
Myeloma	Both Sexes	56,508	67,424	67,605	89,416	103,463
	Male	30,245	36,895	36,980	47,990	56,338
	Female	26,263	30,529	30,625	41,426	47,125
Leukemia	Both Sexes	120,252	139,986	140,426	312,923	345,422
	Male	70,027	82,564	82,799	177,810	197,506
	Female	50,225	57,422	57,627	135,113	147,916
Acute Lymphocytic Leukemia	Both Sexes	17,081	17,590	17,590	71,898	72,647
	Male	9,480	9,693	9,693	39,375	39,666
	Female	7,601	7,897	7,897	32,523	32,981
Childhood (Ages 0-19)	Both Sexes	65,893	65,980	66,533	326,769	327,259
	Male	34,508	34,555	34,858	167,928	168,153
	Female	31,385	31,425	31,675	158,841	159,106
Kaposi Sarcoma	Both Sexes	7,384	7,975	7,975	26,300	27,684
	Male	6,836	7,367	7,367	24,829	26,079
	Female	548	608	608	1,471	1,605
Mesothelioma	Both Sexes	3,247	4,116	4,116	4,957	5,962
	Male	2,341	2,982	2,982	3,042	3,748
	Female	906	1,134	1,134	1,915	2,214

^a U.S. 2012 cancer prevalence counts are based on 2012 cancer prevalence proportions from the SEER 9 registries and 1/1/2012 U.S. population estimates based on the average of 2011 and 2012 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever
^d (d) First invasive tumor for each cancer site diagnosed during the previous 37 years (1975-2011)
^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2007-2011)
 For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2007; Melanoma in 2008.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 37-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2012. In method (d) the 1981 melanoma is counted for the melanoma and all sites 37-year limited duration prevalence. The 2007 breast cancer is counted for the breast 5-year and 37-year limited duration prevalence. In method (e) the 2007 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2008 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.23
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2012^a
By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	6,464,529	19,057	42,522	87,325	156,133	356,474	907,855	1,732,881	3,162,283
Females	7,311,722	17,006	36,354	89,937	229,430	636,759	1,353,262	1,832,064	3,116,909
Oral Cavity & Pharynx									
Males	193,779	73	416	1,506	3,443	14,067	46,864	62,089	65,320
Females	97,329	96	569	1,562	3,831	8,690	18,524	24,531	39,526
Esophagus									
Males	27,808	0	0	34	126	993	4,575	10,168	11,912
Females	7,973	0	0	11	11	207	1,315	2,059	4,369
Stomach									
Males	43,975	0	46	105	596	2,524	7,100	12,229	21,374
Females	32,854	3	23	172	691	2,440	4,745	7,157	17,623
Colon & Rectum									
Males	579,901	11	93	1,215	5,831	26,335	84,353	142,161	319,901
Females	589,028	0	105	1,463	5,773	23,768	72,770	115,560	369,590
Liver & Intrahep									
Males	36,063	560	460	615	605	1,716	11,082	13,605	7,421
Females	14,671	438	522	404	506	925	3,227	4,037	4,612
Pancreas									
Males	22,783	34	18	152	297	1,722	4,835	7,158	8,566
Females	22,919	0	33	237	479	1,550	4,120	6,272	10,228
Larynx									
Males	71,414	0	0	91	244	1,657	10,356	21,554	37,512
Females	17,438	0	0	47	128	806	3,474	4,783	8,200
Lung & Bronchus									
Males	184,230	34	75	504	1,243	5,258	24,519	55,147	97,451
Females	224,578	34	92	414	1,489	6,994	30,650	60,573	124,332
Melanoma of the Skin									
Males	489,614	45	685	5,156	17,606	45,367	99,463	137,601	183,691
Females	506,973	102	812	10,505	34,549	73,225	119,346	119,937	148,497

^a U.S. 2012 cancer prevalence counts are based on 2012 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2012 U.S. population estimates based on the average of 2011 and 2012 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 37 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.23 - continued
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2012^a
 By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	15,499	0	0	11	134	699	1,855	4,533	8,267
Females	2,975,314	11	35	3,037	35,604	214,136	559,716	824,053	1,338,721
Cervix									
Females	249,512	0	68	2,062	15,420	41,029	59,636	58,895	72,402
Corpus & Uterus, NOS									
Females	621,612	11	23	614	5,890	24,821	91,757	174,495	324,000
Ovary ^d									
Females	192,446	77	1,080	3,491	6,874	18,099	42,498	51,208	69,119
Prostate									
Males	2,795,592	34	47	102	293	20,286	240,483	807,991	1,726,357
Urinary Bladder									
Males	430,485	56	117	541	2,355	10,502	43,269	104,139	269,506
Females	146,918	45	34	208	1,046	4,028	13,688	31,217	96,652
Kidney & Renal Pelvis									
Males	223,683	1,445	2,452	2,765	4,922	19,349	43,876	64,800	84,074
Females	152,242	1,519	2,612	2,882	4,794	12,658	26,698	37,929	63,150
Hodgkin Lymphoma									
Males	98,082	237	2,413	9,323	16,360	23,948	22,943	15,053	7,806
Females	91,544	39	1,969	9,432	16,470	22,866	20,748	12,271	7,749
Non-Hodgkin Lymphoma									
Males	289,004	794	3,674	8,038	13,729	29,671	55,734	74,542	102,823
Females	260,621	475	1,812	4,755	8,981	21,174	43,182	63,503	116,739
Myeloma									
Males	48,074	0	6	121	521	3,285	8,685	16,099	19,356
Females	41,584	0	0	28	392	2,271	7,446	12,033	19,413
Leukemia									
Males	180,231	6,723	13,446	13,043	11,701	14,648	25,247	36,927	58,495
Females	138,158	5,979	10,128	12,020	10,156	10,667	16,951	24,384	47,873
Acute Lymphocytic Leuk									
Males	41,055	5,618	11,450	9,948	6,685	4,256	1,672	861	564
Females	34,121	5,033	8,635	8,663	5,668	3,311	1,318	916	579

^a U.S. 2012 cancer prevalence counts are based on 2012 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2012 U.S. population estimates based on the average of 2011 and 2012 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 37 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.